This HTML5 document contains 91 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n17http://linked.opendata.cz/resource/drugbank/drug/DB00957/identifier/chemspider/
n11http://linked.opendata.cz/resource/mesh/concept/
n14http://linked.opendata.cz/resource/drugbank/company/
n21http://linked.opendata.cz/resource/drugbank/drug/DB00957/identifier/chebi/
foafhttp://xmlns.com/foaf/0.1/
n4http://linked.opendata.cz/resource/drugbank/mixture/
n25http://linked.opendata.cz/resource/drugbank/drug/DB00957/identifier/wikipedia/
n6http://linked.opendata.cz/resource/drugbank/drug/DB00957/identifier/pharmgkb/
n13http://bio2rdf.org/drugbank:
n19http://linked.opendata.cz/resource/drugbank/drug/DB00957/identifier/pubchem-compound/
admshttp://www.w3.org/ns/adms#
n9http://www.rxlist.com/cgi/generic/
n22http://linked.opendata.cz/resource/drugbank/patent/
n23http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
n16http://linked.opendata.cz/resource/drugbank/drug/DB00957/identifier/kegg-drug/
n20http://linked.opendata.cz/resource/drugbank/drug/DB00957/identifier/pubchem-substance/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n24http://linked.opendata.cz/resource/drugbank/medicinal-product/
n18http://linked.opendata.cz/resource/drugbank/drug/DB00957/identifier/drugbank/
n10http://linked.opendata.cz/ontology/mesh/
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n7http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#

Statements

Subject Item
n2:DB00957
rdf:type
n3:Drug
n3:description
Norgestimate is a form of progesterone, which is a female hormone important for the regulation of ovulation and menstruation. Norgestimate is used with estradiol to treat the symptoms of menopause.
n3:group
approved
n3:halfLife
12-30 hours
n3:indication
For the prevention of pregnancy
owl:sameAs
n13:DB00957 n23:DB00957
dcterms:title
Norgestimate
adms:identifier
n6:PA164744346 n16:D05209 n17:5022837 n18:DB00957 n19:6540478 n20:46507381 n21:50815 n25:Norgestimate
n3:mechanismOfAction
Norgestimate binds to androgen and progestogen receptors. Target cells include the female reproductive tract, the mammary gland, the hypothalamus, and the pituitary. Once bound to the receptor, progestins like Norgestimate will slow the frequency of release of gonadotropin releasing hormone (GnRH) from the hypothalamus and blunt the pre-ovulatory LH (luteinizing hormone) surge.
n3:packager
n14:271B42F2-363D-11E5-9242-09173F13E4C5 n14:271B42FC-363D-11E5-9242-09173F13E4C5 n14:271B42F1-363D-11E5-9242-09173F13E4C5 n14:271B42FB-363D-11E5-9242-09173F13E4C5 n14:271B42EF-363D-11E5-9242-09173F13E4C5 n14:271B42F0-363D-11E5-9242-09173F13E4C5 n14:271B42F8-363D-11E5-9242-09173F13E4C5 n14:271B42F9-363D-11E5-9242-09173F13E4C5 n14:271B42F6-363D-11E5-9242-09173F13E4C5 n14:271B42F7-363D-11E5-9242-09173F13E4C5 n14:271B42F4-363D-11E5-9242-09173F13E4C5 n14:271B42F5-363D-11E5-9242-09173F13E4C5 n14:271B42F3-363D-11E5-9242-09173F13E4C5 n14:271B42FA-363D-11E5-9242-09173F13E4C5
n3:patent
n22:5382573 n22:7320970
n3:synonym
Dexnorgestrel Acetime (17alpha)-17-(Acetyloxy)-13-ethyl-18,19-dinorpregn-4-en-20-yn-3-one 3-oxime Norgestimatum Norgestimato (+)-13-Ethyl-17-hydroxy-18,19-dinor-17alpha-pregn-4-en-20-yn-3-one oxime acetate (ester) D-13beta-Ethyl-17alpha-ethynyl-17beta-acetoxygon-4-en-3-one oxime
n3:foodInteraction
Take with food. Avoid alcohol. Increase dietary intake of magnesium, folate, vitamin B6, B12, and/or consider taking a multivitamin. Avoid excessive quantities of coffee or tea (Caffeine). Take at the same time everyday.
n3:mixture
n4:271B42EA-363D-11E5-9242-09173F13E4C5 n4:271B42E7-363D-11E5-9242-09173F13E4C5 n4:271B42E8-363D-11E5-9242-09173F13E4C5 n4:271B42ED-363D-11E5-9242-09173F13E4C5 n4:271B42EE-363D-11E5-9242-09173F13E4C5 n4:271B42EB-363D-11E5-9242-09173F13E4C5 n4:271B42EC-363D-11E5-9242-09173F13E4C5 n4:271B42E9-363D-11E5-9242-09173F13E4C5
n10:hasConcept
n11:M0068439
foaf:page
n9:norgestimest.htm
n3:IUPAC-Name
n7:271B4307-363D-11E5-9242-09173F13E4C5
n3:InChI
n7:271B430D-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n7:271B430C-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n7:271B4309-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n7:271B430A-363D-11E5-9242-09173F13E4C5
n3:SMILES
n7:271B430B-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n7:271B4305-363D-11E5-9242-09173F13E4C5
n3:logP
n7:271B4306-363D-11E5-9242-09173F13E4C5 n7:271B4303-363D-11E5-9242-09173F13E4C5 n7:271B431E-363D-11E5-9242-09173F13E4C5
n3:logS
n7:271B4304-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Acceptor-Count
n7:271B4313-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n7:271B4314-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n7:271B430E-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n7:271B430F-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n7:271B4311-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n7:271B4310-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n7:271B4312-363D-11E5-9242-09173F13E4C5
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
35189-28-7
n3:category
n3:containedIn
n24:271B4301-363D-11E5-9242-09173F13E4C5 n24:271B4302-363D-11E5-9242-09173F13E4C5 n24:271B42FF-363D-11E5-9242-09173F13E4C5 n24:271B4300-363D-11E5-9242-09173F13E4C5 n24:271B42FD-363D-11E5-9242-09173F13E4C5 n24:271B42FE-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n7:271B4319-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n7:271B431B-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n7:271B431C-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n7:271B431D-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n7:271B4318-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n7:271B4317-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n7:271B431A-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n7:271B4308-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n7:271B4315-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n7:271B4316-363D-11E5-9242-09173F13E4C5